New Anxiety Medications in 2026

By the clinical team at Next Step Psychiatry • Lilburn, GA

Why We Need New Anxiety Medications

For decades, the options for treating anxiety have remained largely the same: SSRIs, SNRIs, benzodiazepines, and buspirone. While these medications help millions of people, they don’t work for everyone—and they come with significant limitations. SSRIs take weeks to work. Benzodiazepines are addictive. Buspirone doesn’t work fast enough for many patients. An estimated 30–40% of people with anxiety disorders don’t achieve adequate relief from current treatments.

That’s why the pipeline of new anxiety medications is so exciting. For the first time in years, genuinely novel approaches are in late-stage development.

MM120: A Psychedelic-Based Breakthrough for GAD

MM120, developed by MindMed, is perhaps the most groundbreaking anxiety treatment in the pipeline. It uses a precisely controlled, single dose of a lysergic acid derivative (related to LSD) administered under medical supervision. In Phase 2 trials, a single dose of MM120 produced significant and sustained improvement in generalized anxiety disorder symptoms, with effects lasting weeks to months after just one treatment.

The FDA granted MM120 Breakthrough Therapy designation, fast-tracking its development. If approved, it would represent a paradigm shift—treating anxiety with a single dose rather than daily medication.

Fasedienol: A Nasal Spray for Social Anxiety

Developed by Vistagen Therapeutics, fasedienol is a pherine-class medication delivered as a nasal spray. It works through nasal chemosensory neurons that send signals directly to brain regions involved in anxiety and social behavior—bypassing the bloodstream entirely. This rapid, targeted delivery means faster onset and potentially fewer systemic side effects.

Early trial results showed significant improvement in social anxiety disorder symptoms. Fasedienol could be a game-changer for the estimated 15 million Americans with social anxiety who often can’t tolerate or don’t respond to current medications.

GlyphAllo: Fast-Acting Depression and Anxiety Relief

Seaport Therapeutics is developing GlyphAllo (Glyph Allopregnanolone) for major depressive disorder with significant anxiety. It works by modulating GABA receptors—similar to benzodiazepines but through a different mechanism that may avoid dependence. Early data suggests rapid onset of antidepressant and anxiolytic effects, potentially within days.

GlyphAllo uses a proprietary delivery system designed to improve the bioavailability of allopregnanolone, a naturally occurring neurosteroid that your brain already produces in small amounts.

What This Means for Patients Today

While these medications are still in development, they represent real hope for patients who haven’t found relief with current options. In the meantime, existing treatments remain effective for the majority of people. At Next Step Psychiatry, we stay at the forefront of psychiatric treatment—we were early adopters of Spravato treatment and we’ll be among the first to offer these new medications when they become available.

If you’re struggling with anxiety that hasn’t responded to treatment, don’t give up. Better options are coming, and there may be approaches you haven’t tried yet.

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. If you or someone you know is in crisis, call 911 or the 988 Suicide & Crisis Lifeline.